Stocktoria
BIO-RAD LABORATORIES, INC. BIO
BIO-RAD LABORATORIES, INC. (BIO) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $2.6B at a 29.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.32 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-01 | Wells Fargo | Equal-Weight (main) |
| 2026-04-07 | Citigroup | Neutral (down) |
| 2026-02-16 | Wells Fargo | Equal-Weight (main) |
| 2025-10-30 | Citigroup | Buy (main) |
| 2025-10-30 | Wells Fargo | Equal-Weight (main) |
| 2025-08-01 | RBC Capital | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.226 |
| Retained earnings / assets | 0.773 |
| EBIT / assets | 0.004 |
| Equity / liabilities | 2.387 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BIO | BIO-RAD LABORATORIES, INC. | 5/9 | 6.54 | 10.7 | +0.7% |
| RVTY | REVVITY, INC. | 6/9 | 3.86 | 52.3 | +3.7% |
| WAT | WATERS CORP /DE/ | 4/9 | 10 | 55.1 | +7% |
| BRKR | BRUKER CORP | 4/9 | 2.98 | — | +2.1% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | 5/9 | — | 29.4 | +4% |
| ILMN | ILLUMINA, INC. | 7/9 | 3.04 | 31.4 | -0.7% |
| TXG | 10x Genomics, Inc. | 4/9 | 1.63 | — | +5.2% |
About BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
FAQ
Is BIO financially healthy?
BIO-RAD LABORATORIES, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does BIO pay a dividend?
No, BIO-RAD LABORATORIES, INC. does not currently pay a dividend.
How profitable is BIO?
In FY2025, BIO-RAD LABORATORIES, INC. had a net margin of 29.4% and a return on equity of 10.2%.
Is BIO overvalued or undervalued?
BIO-RAD LABORATORIES, INC. trades at about 13.0× trailing earnings — below its 10-year norm (10-year range 4.3×–216.0×, median 34.4×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for BIO?
The average Wall-Street price target for BIO-RAD LABORATORIES, INC. is $297.00, about 18.0% below the recent price, from 5 analysts.
Is BIO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BIO-RAD LABORATORIES, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 10.7×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.